Comparison between Anthem Biosciences IPO and Aye Finance IPO.
Anthem Biosciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Aye Finance IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Anthem Biosciences IPO is up to ₹3,395.00 Cr whereas the issue size of the Aye Finance IPO is up to ₹1,010.00 Cr. The final issue price of Anthem Biosciences IPO is ₹570.00 per share and of Aye Finance IPO is ₹129.00 per share.
| Anthem Biosciences IPO | Aye Finance IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹2 per share |
| Issue Price (Lower) | ₹540.00 per share | ₹122.00 per share |
| Issue Price (Upper) | ₹570.00 per share | ₹129.00 per share |
| Issue Price (Final) | ₹570.00 per share | ₹129.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹50.00 per share | |
| Market Lot Size | 26 shares | 116 shares |
| Fresh Issue Size | 0 shares | 5,50,38,759 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹710.00 Cr |
| OFS Issue Size | 5,95,75,319 shares | 2,32,55,812 shares |
| OFS Issue Size (Amount) | up to ₹3,395.00 Cr | up to ₹300.00 Cr |
| Issue Size Total | 5,95,75,319 shares | 7,82,94,571 shares |
| Issue Size Total (Amount) | up to ₹3,395.00 Cr | up to ₹1,010.00 Cr |
Anthem Biosciences IPO opens on Jul 14, 2025, while Aye Finance IPO opens on Feb 09, 2026. The closing date of Anthem Biosciences IPO and Aye Finance IPO is Jul 16, 2025, and Feb 11, 2026, respectively.
| Anthem Biosciences IPO | Aye Finance IPO | |
|---|---|---|
| Anchor Bid Date | Jul 11, 2025 | Feb 06, 2026 |
| Issue Open | Jul 14, 2025 | Feb 09, 2026 |
| Issue Close | Jul 16, 2025 | Feb 11, 2026 |
| Basis Of Allotment (Tentative) | Jul 17, 2025 | Feb 12, 2026 |
| Initiation of Refunds (Tentative) | Jul 18, 2025 | Feb 13, 2026 |
| Credit of Share (Tentative) | Jul 18, 2025 | Feb 13, 2026 |
| Listing date (Tentative) | Jul 21, 2025 | Feb 16, 2026 |
| Anchor Lockin End date 1 | Aug 15, 2025 | Mar 13, 2026 |
| Anchor Lockin End date 2 | Oct 14, 2025 | May 12, 2026 |
Anthem Biosciences IPO P/E ratio is 70.62, as compared to Aye Finance IPO P/E ratio of 14.11.
| Anthem Biosciences IPO | Aye Finance IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Anthem Biosciences Ltd.'s revenue increased by 30% and profit after tax (PAT) rose by 23% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 76.87 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 74.68 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 70.62 | 14.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹31867.39 Cr. | ₹3183.52 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 20.82% | 12.12% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 26.88% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.05 | 2.73 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹8.07 | ₹9.14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 20.82% | 12.12% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Anthem Biosciences IPO Retail Individual Investors (RII) are offered 2,07,95,834 shares while in Aye Finance IPO retail investors are offered 2,07,95,834 shares. Qualified Institutional Buyers (QIB) are offered 1,18,83,333 shares in Anthem Biosciences IPO and 2,34,88,372 shares in Aye Finance IPO.
| Anthem Biosciences IPO | Aye Finance IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,78,24,999 shares | 3,52,32,558 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 1,18,83,333 shares | 2,34,88,372 shares |
| NII | 89,12,500 shares | 1,17,44,185 shares |
| RII | 2,07,95,834 shares | 78,29,456 shares |
| Employee | 1,58,653 shares | 0 shares |
| Others | ||
| Total | 5,95,75,319 shares | 7,82,94,571 shares |
Anthem Biosciences IPO subscribed 67.42x in total, whereas Aye Finance IPO subscribed 1.04x.
| Anthem Biosciences IPO | Aye Finance IPO | |
|---|---|---|
| QIB (times) | 192.80x | 1.62x |
| NII (times) | 44.70x | 0.05x |
| Big NII (times) | 51.66x | 0.02x |
| Small NII (times) | 30.80x | 0.11x |
| RII (times) | 5.98x | 0.81x |
| Employee (times) | 6.99x | |
| Other (times) | ||
| Total (times) | 67.42x | 1.04x |
